|
|
||||||||


,¶
,¶
,||
* Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland;
Swiss Institute for Bioinformatics, Lausanne, Switzerland;
Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne, Switzerland;
Swiss Institute for Experimental Cancer Research, Epalinges, Switzerland;
¶ National Center of Competence in Research Molecular Oncology, Epalinges, Switzerland; and
|| Multidisciplinary Oncology Center, Lausanne, Switzerland
In HLA-A2 individuals, the CD8 T cell response against the differentiation Ag Melan-A is mainly directed toward the peptide Melan-A2635. The murine Melan-A2433 sequence encodes a peptide that is identical with the human Melan-A2635 decamer, except for a Thr-to-Ile substitution at the penultimate position. Here, we show that the murine Melan-A2433 is naturally processed and presented by HLA-A2 molecules. Based on these findings, we compared the CD8 T cell response to human and murine Melan-A peptide by immunizing HLA-A2 transgenic mice. Even though the magnitude of the CTL response elicited by the murine Melan-A peptide was lower than the one elicited by the human Melan-A peptide, both populations of CTL recognized the corresponding immunizing peptide with the same functional avidity. Interestingly, CTL specific for the murine Melan-A peptide were completely cross-reactive against the orthologous human peptide, whereas anti-human Melan-A CTL recognized the murine Melan-A peptide with lower avidity. Structurally, this discrepancy could be explained by the fact that Ile32 of murine Melan-A2433 created a larger TCR contact area than Thr34 of human Melan-A2635. These data indicate that, even if immunizations with orthologous peptides can induce strong specific T cell responses, the quality of this response against syngeneic targets might be suboptimal due to the structure of the peptide-TCR contact surface.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |